PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-small Cell Lung Cancer
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) ECOG Performance Status of 0-1 within 28 days prior to registration. 2) Patients must have undergone complete surgical resection of their stage I (tumors = 4cm), IIA, IIB, and select IIIA (T3N1-2, T4N0-2) NSCLC according to the AJCC 8th edition with negative margins (R0). 3) Squamous or non-squamous NSCLC histology. 4) Surgery for this lung cancer must be completed < 60 days prior to starting treatment.
You may not be eligible for this study if the following are true:
-
1) Tumors that have any component of small cell or large cell neuroendocrine histology are NOT eligible. 2) Tumors that are known to harbor EGFR mutations or ALK re-arrangements are NOT eligible. 3) Prior chemotherapy, radiation therapy, or immunotherapy is NOT allowed for the treatment of this lung cancer. 4) Prior chemotherapy and/or radiation therapy is permissible for the treatment of other previous cancers, but must have been completed at least 3 months prior to registration for this trial.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
